Nonrandomized comparison of neurofibromatosis type 1 and non–neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low‐grade glioma: A report from the Children's Oncology Group
Joann L. Ater(Children's Oncology Group), Ian F. Pollack(Children's Hospital of Pittsburgh), Richard Sposto(Children's Hospital of Los Angeles), Claire Mazewski(Children's Oncology Group), Gilbert Vézina(Children's Oncology Group), David R. Freyer(University of Southern California), Roger J. Packer(Children's Hospital of Philadelphia), Caihong Xia(University of Southern California), Timothy N. Booth(Children's Oncology Group)
Cited by 121
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
|JNCI Journal of the National Cancer Institute|2009|530
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|433